A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Thiru M. Annaswamy, MD MA a, * , Monica Verduzco-Gutierrez, MD b, Lex Frieden, MA, LLD c
a VA North Texas Health Care System, UT Southwestern Medical Center, Dallas, TX, USA
b The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
c University of Texas Health Science Center at Houston, Houston, TX, USA
abstract
The COVID-19 pandemic has forced a rapid adoption of telemedicine over traditional in-person visits due to social restrictions. While telemedicine improves access and reduces barriers to healthcare access for many, several barriers and challenges remain for persons with disabilities, and novel challenges have been exposed, many of which may persist long-term.
The challenges and barriers that need to be systematically addressed include: Infrastructure and access barriers, operational challenges, regulatory barriers, communication barriers and legislative barriers.
Persons with disabilities are a vulnerable population and little attention has been placed on their healthcare access during the pandemic. Access and communication during a healthcare encounter are important mediators of outcomes for persons with disabilities. Significant, long-term changes in technological, regulatory, and legislative infrastructure and custom solutions to unique patient and health system needs are required to address these barriers going forward in order to improve healthcare access and outcomes for persons with disabilities.
ARTICLE INFO
Article history:
Received 6 June 2020 Received in revised form 22 June 2020 Accepted 29 June 2020
Keywords:
Telemedicine Telerehabilitation Health services accessibility Health legislation Disability studies
Background
Access to healthcare is a significant metric for healthcare outcomes. The COVID-19 pandemic has forced a rapid adoption of virtual telemedicine instead of traditional in-person visits due to social restrictions. While telemedicine improves access and reduces barriers to healthcare access for many, several barriers and challenges remain for persons with disabilities, and novel challenges have been exposed during the COVID-19 pandemicdmany of which may persist long-term.
Persons with disabilities are a vulnerable population with unique social, economic, and environmental disadvantages. They have distinct disparities that influence healthcare access, compromise their health, and ultimately lead to them having far worse healthcare outcomes than persons without disabilities.1 61 million adults in the U.S. live with a disability.2 Persons with disabilities are older, poorer, have significantly higher rates of obesity, diabetes, heart disease and smoking prevalence, and are also less likely to have a regular healthcare provider.2 They are less likely to afford healthcare, and more likely to have unmet healthcare needs. Furthermore, rural areas have a higher percentage of persons with disabilities than urban areas.3
Previously, telemedicine functioned as an alternative to traditional in-person healthcare access. If a person with disability had barriers accessing or communicating with healthcare providers viatelemedicine, they could revert to in-person care. However, with telemedicine now being the primarydand often onlydmeans of access, these barriers must be addressed and new protections for maintaining and improving healthcare equity delivered via telemedicine need to be in place. In the era of COVID-19 and beyond, telemedicine can no longer be considered a “complement” to inperson care. Rather, it should be viewed and reviewed as an “alternative” for in-person healthcare, because its use is likely to be sustained at a much higher rate post-COVID-194 even as traditional in-person healthcare visits resume. This in turn means that several adjacent issues need to be addressed. Previously, all healthcare access and communication issues for persons with disability focused (almost exclusively) on what occurred during in-person visits, with specific attention to: a) Physical setup and access to clinics, hospitals, and other healthcare facilities; b) Equipment used during delivery of healthcare for interaction between persons with disabilities and providers; and c) Communication and patient education tools. Now, all these issues must be revisited and viewed through a new perspective with telemedicine currently being the primary means and likely to remain a highly relevant means of healthcare access beyond COVID-19.
Some reported benefits of telemedicine for persons with disability include lower cost of care, lower transportation costs, improved medication reconciliation communication, less exposure to communicable diseases especially during a pandemic, and decreased need for paid personal assistance services.5 However, given the current spotlight on telemedicine, the time is ripe to systematically assess the benefifits, risks, and opportunities for healthcare encounters via telemedicine for persons with disabilities.
Barriers and challenges
There is a need to systematically address the following issues:
Infrastructure and Access Barriers: A huge obstacle for appropriate utilization of telemedicine is that broadband - fast internetdis inaccessible in many rural and low-income communities (even in cities) where many persons with disabilities live, largely due to the absence of infrastructure. There has traditionally not been enough investment in these communities mostly because there are neither legal requirements nor financial benefits or incentives for private providers and network companies to provide such access.6 Despite subsidies and assistance programs to make such technology affordable for those people who may have infrastructure available, telemedicine access for persons with disabilities living in these communities is likely suboptimal. In addition, user interface issues such as screen reader, sign language, captions, magnification, color, and contrast also need to be addressed. Bioperipherals, such as devices that measure blood pressure and other vital signs need to be customized for use in tele-evaluation of persons with disabilities.7 Design and development of novel bioperipherals is needed to enhance clinicians’ ability to tele-examine persons with disabilities who may have manual dexterity or physical mobility problems that interfere with their ability to interact with such bioperipherals.
Operational and Systems Challenges: Telehealth platforms are akin to electronic medical records with inherent software and hardware costs with significant resources currently being channeled to improve its “quality of experience”. In addition, healthcare systems and providers are under increased stress to maintain clinical productivity via telemedicine. It is unclear how these new costs will be commoditized; there is a risk that a proportion of such costs may be transferred to vulnerable populations such as persons with disabilities who may not be able to afford them. In addition, many healthcare institutions, including academic institutions and facilities that depend greatly on graduate medical trainees have not integrated telemedicine into their routine healthcare delivery as seamlessly as some private practices. This has significantly impacted access to telemedicine for populations such as persons with disabilities who often rely on healthcare delivered through trainees (via safety net health insurance programs such as Medicaid and Medicare).
Logistical Challenges: Traditional in-person healthcare is often seamlessly coordinated with ancillary healthcare services such as laboratory testing and diagnostic studies that often need to be timed in advance of such visits. Because these ancillary services still require persons with disabilities to go in-person to a testing center navigating and coordinating such logistics can be particularly challenging.
Regulatory Barriers: During the healthcare emergency due to the COVID-19 pandemic, several telemedicine regulatory barriers have been eased such as practicing across state lines, local credentialing and privileging issues, prescription and controlled substances regulations, and billing rules. Once we move past the state of emergency, it is unknown if these rules will be reinstated. For example, persons with disabilities currently receive telemedicine care across statelines due to travel restrictions during COVID-19 because of waived restrictions. However, it is unclear if they will continue to be able to receive such care once those waivers expire, if they have travel limitations due to their disability and need to receive telemedicine care across statelines. There is a need for a permanently legislated, coherent, standardized, nation-wide telehealth regulatory framework instead of a hodgepodge of conflicting local, state, insurance, and federal regulations.
Communication Barriers: Most telemedicine platforms do not have custom features to ease healthcare communications for persons who are deaf or blind or for persons with cognitive disabilities. Furthermore, there is a dearth of patient education materials for persons with language and literacy challenges. Providers who are utilizing telemedicine may not understand and be able to address the accessibility issues with their patients even if the system is designed correctly. Web accessibility standards that accommodate persons with disabilities need to be enforced on telemedicine platforms.8
Legislative Barriers: The Americans with Disabilities Act (ADA) was passed before the Internet became a widely used public service. The design standards of the ADA address physical spaces including healthcare facilities, but not virtual spaces or services such as telemedicine.9 In principle, the ADA’s coverage extends to the Internet and its virtual world. However, the law does not prescribe standards for accessibility or directions for making websites accessible. The World Wide Web Consortium publishes accessibility guidelines,10 but these are voluntary and not legally enforceable. The lack of regulations under the ADA that specifically address web accessibility and dictate the technical standards and implementation timelines for compliance leaves businesses, advocates and courts at odds. There is a pressing need to promulgate pertinent regulations under the ADA. Consistent regulations should be issued under Section 504 of Rehabilitation Act of 1973 and Section 1557 of the Affordable Care Act. Technology companies that design and distribute telemedicine products must be subject to these laws, by considering them and their products as health-care-not technological - organizations and products.
Unique Challenges: Persons with disabilities may also face unique challenges specific to their type of disability while accessing healthcare via telemedicine. For example, effective communication may be challenging for persons with intellectual disability. Telephysical assessment of persons with mobility or manual dexterity disability may be challenging due to difficulties interacting with the virtual interface or bioperipheral device. Persons with communication disability such as those with neurological or speech disorders may need unique solutions for telemedicine to be effective. Similarly, the virtual interfaces need to be customized to accommodate for the disabilities of persons with mental illness or autism spectrum disorders. These unique challenges need custom solutions so that persons with disabilities are not left behind during this era of telemedicine.
Conclusion
It is evident that COVID-19 is not the great equalizer. Persons with disabilities are a vulnerable population and little attention has been placed on their healthcare access during the pandemic. Access and communication during a healthcare encounter are important mediators of outcomes. Telemedicine has replaceddrather than complementeddin-person visits during COVID-19 and its use is likely to be sustained at a high-level post COVID-19. While it has facilitated access for some, several challenges and barriers remain that must be systematically assessed. Significant, long-term changes in technological, regulatory, and legislative infrastructure and custom solutions to unique patient and health system needs are required to address these barriers going forward in order to improve healthcare access and outcomes for persons with disabilities.
Funding or conflicts of interest statement
None of the authors have any relevant disclosures related to the funding of the project or any financial benefits received in relation to this research.
Acknowledgments
We acknowledge and thank Vinh Nguyen, an attorney and Director of the Southwest ADA Technical Assistance Center, Houston, TX for his contributions to this report.
References
1. Smith CA. Healthcare disparities in people with disabilities: is there a cure? South Med J. 2019;112(2):98e100. https://doi.org/10.14423/SMJ.0000000000000928.
2. Centers for Disease Control and Prevention. Disability impacts all of us. Accessed May 18, 2020 https://www.cdc.gov/ncbddd/disabilityandhealth/infographicdisability-impacts-all.html. Accessed September 9, 2019.
3. Centers for Disease Control and Prevention. Prevalence of Disability and Disability Types by Urban-Rural County Classification e United States; 2016. Accessed May 18, 2020 https://www.cdc.gov/ncbddd/disabilityandhealth/features/disability prevalence-rural-urban.html. Accessed November 18, 2019.
4. Gilbert AW, Billany JCT, Adam R, et al. Rapid implementation of virtual clinics due to COVID-19: report and early evaluation of a quality improvement initiative. BMJ Open Qual. 2020;9(2), e000985. https://doi.org/10.1136/bmjoq-2020-000985.
5. Agha Z, Schapira RM, Maker AH. Do we want to talk about cost effectiveness as a benefit? Cost effectiveness of telemedicine for the delivery of outpatient pulmonary care to a rural population. Telemed J e Health. 2002;8(3):281e291.
6. Internet Options for Low and Fixed Income households. Last updated: 5/19/ 2020 https://broadbandnow.com/guides/low-income-internet Author: Tyler Cooper. Accessed May 24, 2020.
7. Scott Kruse C, Karem P, Shifflett K, Vegi L, Ravi K, Brooks M. Evaluating barriers to adopting telemedicine worldwide: a systematic review. J Telemed Telecare. 2018;24(1):4-12. https://doi.org/10.1177/1357633X16674087.
8. W3C. The website of the world wide web consortium’s web accessibility initiative. https://www.w3.org/WAI/. www.w3.org. Accessed May 18, 2020.
9. Powers GM, Frieden L, Nguyen V. Telemedicine: access to health care for people with disabilities. Houst J health law policy. 2017;17:7e20.
10. Danino Nicky. W3C accessibility guidelines. Last updated: 8/7/2001 https:// www.sitepoint.com/w3c-accessibility-guidelines/. Accessed June 14, 2020.
This article is excerpted from the Disability and Health Journal by Wound World.
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。